$0.46
-0.02 (-4.24%)
Open$0.47
Previous Close$0.48
Day High$0.52
Day Low$0.45
52W High$4.34
52W Low$0.52
Volume—
Avg Volume205.8K
Market Cap8.22M
P/E Ratio—
EPS$-1.61
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+5,540.5% upside
Current
$0.46
$0.46
Target
$25.98
$25.98
$20.93
$25.98 avg
$39.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.75M | 4.21M | 3.91M |
| Net Income | 909.1K | 778.9K | 578.2K |
| Profit Margin | 19.1% | 18.5% | 14.8% |
| EBITDA | 1.38M | 1.12M | 1.11M |
| Free Cash Flow | 932.9K | 1.05M | 869.6K |
| Rev Growth | +21.8% | +17.5% | +9.1% |
| Debt/Equity | 0.24 | 0.30 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |